The past few weeks have seen a spate of pharma manufacturing cuts, with Actavis, Merck and Pfizer all whacking jobs. And Pfizer has continued its busy end to 2013 by revealing it is to close a packaging plant in Ireland, laying off 150 workers in the process.
Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.
In the latest round of layoffs, Dendron plans to save $125 million in operating expenses by cutting its headcount by 15%. Around 150 full-time employees are set to lose their jobs over the next nine months as Dendreon cuts its R&D and marketing budgets in a bid to achieve profitability.
Shire is prepping a plan to cut back on its sizable research operations in Basingstoke, U.K.--another setback for the country's research industry with Novartis axing more than 500 staffers and consultants in Horsham following major blows from AstraZeneca and Pfizer.
The pharma industry led the layoffs charge during the month of October, accounting for 10,585 of the job cuts announced.
Novartis is bringing the ax down on close to 400 R&D jobs at its respiratory R&D center in West Sussex in the U.K., signaling that the restructuring is part of a broader global realignment.
Last month's news that Merck is to lay off 8,500 staffers began speculation as to exactly where the ax would fall. Since then, pink slips have begun circulating and the fate of staff at the manufacturing unit has become clearer: 500 workers at the West Point plant will start the New Year looking for a new job.
That Teva workers are striking to protest job cuts isn't all that unusual in the pharma business these days. That they're protesting executive pay is somewhat more unusual. That a prominent shareholder advises an accompanying pay cut for top executives and directors? That's definitely unusual.
Amarin couldn't wait for the FDA's final decision on whether to grant its fish oil drug Vascepa approval for a wider use. With the handwriting on the wall, its stock price in the toilet and cash burning, the drugmaker said today that it will cleave half of its staff.
Teva Pharmaceutical Industries will back off its layoff plans in Israel--at least for now. Thanks to vociferous and colorful opposition from labor, plus worker support from politicians, Teva now pledges to negotiate with unions before cutting jobs.